Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury
NCT02923817Phase 2Unknown
- Sponsor
- Da Nang Hospital
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in spinal cord injury (SCI), sponsored by Da Nang Hospital. Primary endpoint: Safety profile and adverse effects of the procedure at 6 months. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02923817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923817.